| dc.contributor.author | Harrison, Paul J | |
| dc.contributor.author | Tunbridge, Elizabeth | |
| dc.date.accessioned | 2019-07-15T09:18:24Z | |
| dc.date.available | 2019-07-15T09:18:24Z | |
| dc.date.issued | 2019-06 | |
| dc.identifier.citation | Paul J. Harrison, Elizabeth M. Tunbridge, Annette C. Dolphin, Jeremy Hall. Voltage-gated calcium channel blockers for psychiatric disorders: genomic reappraisal. The British Journal of Psychiatry, 1-4 24 June 2019 | en |
| dc.identifier.issn | 1472-1465 | |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/263 | |
| dc.description | Published online at: https://doi.org/10.1192/bjp.2019.157
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. | en |
| dc.description.abstract | We reappraise the psychiatric potential of calcium channel blockers (CCBs). First, voltage-gated calcium channels are risk genes for several disorders. Second, use of CCBs is associated with altered psychiatric risks and outcomes. Third, research shows there is an opportunity for brain-selective CCBs, which are better suited to psychiatric indications. | en |
| dc.description.sponsorship | Supported by the NIHR | en |
| dc.language.iso | en | en |
| dc.subject | Bipolar Disorder | en |
| dc.title | Voltage-gated calcium channel blockers for psychiatric disorders: genomic reappraisal | en |
| dc.type | Article | en |